{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:32:16Z","timestamp":1762900336294,"version":"3.41.2"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Safe and effective vaccines against SARS-CoV-2 for children are urgently needed. Here we aimed to assess the safety and immunogenicity of an inactivated COVID-19 vaccine candidate, WIBP-CorV, in participants aged 3-17 years. A randomized, double-blind, placebo-controlled, phase 1\/2 clinical trial was conducted in Henan Province, China, in healthy children aged 3-17 years. 240 participants in phase 1 trial and 576 participants in phase 2 trial were randomly assigned to vaccine or control with an age de-escalation in three cohorts (3-5, 6-12 and 13-17 years) and dose-escalation in three groups (2.5, 5.0 and 10.0\u03bcg\/dose), and received 3 intramuscular injections at day 0, 28, and 56.\u00a0WIBP-CorV showed a promising safety profile with approximately 17% adverse reactions within 30 days after injection and no grade 3 or worse adverse events. The most common adverse reaction was injection site pain, followed by fever, which were mild and self-limiting. The geometric mean titers of neutralizing antibody ranged from 102.2 to 1065.5 in vaccinated participants at 28 days after the third vaccination, and maintained at a range of 14.3 to 218.2 at day 180 after the third vaccination. WIBP-CorV elicited significantly higher titers of neutralizing antibody in the cohort aged 3-5 years than the other two cohorts. There were no detectable antibody responses in all alum-only groups. Taken together, our data demonstrate that WIBP-CorV is safe and well tolerated at all tested doses in participants aged 3-17 years, and elicited robust humoral responses against SARS-CoV-2 lasted for at least 6 months after the third vaccination. This study is ongoing and is registered with www.chictr.org.cn, ChiCTR2000031809. <\/jats:p>","DOI":"10.3389\/fimmu.2022.898151","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T13:11:57Z","timestamp":1656076317000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1\/2 Trial"],"prefix":"10.3389","volume":"13","author":[{"given":"Shengli","family":"Xia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuntao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqing","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongyang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huajun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinguo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunkai","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxiao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wangyang","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuewei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zejun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengli","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuqin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingliang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongli","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shihe","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhui","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuanxuan","family":"Nian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiming","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanshen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,24]]},"reference":[{"key":"B1","unstructured":""},{"key":"B2","unstructured":""},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa712","article-title":"The Importance of Advancing Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Children","volume":"72","author":"Kao","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.4302","article-title":"Association of Age With SARS-CoV-2 Antibody Response","volume":"4","author":"Yang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd6165","article-title":"COVID-19 in Children and Young People","volume":"370","author":"Snape","year":"2020","journal-title":"Science."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002660","article-title":"Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children","volume":"39","author":"Zimmermann","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002899","article-title":"Children and Adolescents With SARS-CoV-2 Infection: Epidemiology, Clinical Course and Viral Loads","volume":"39","author":"Maltezou","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.06.014","article-title":"Multisystem Inflammatory Syndrome in Children (MIS-C) With COVID-19: Insights From Simultaneous Familial Kawasaki Disease Cases","volume":"97","author":"Ebina-Shibuya","year":"2020","journal-title":"Int J Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.15543","article-title":"Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials","volume":"324","author":"Xia","year":"2020","journal-title":"Jama."},{"key":"B10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jama.2021.8565","article-title":"Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial","volume":"326","author":"Al Kaabi","year":"2021","journal-title":"Jama."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.802858","article-title":"Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S2213-2600(21)00220-4","article-title":"BNT162b2 COVID-19 Vaccine and Correlates of Humoral Immune Responses and Dynamics: A Prospective, Single-Centre, Longitudinal Cohort Study in Health-Care Workers","volume":"9","author":"Lustig","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26185","article-title":"Age-Dependent and Gender-Dependent Antibody Responses Against SARS-CoV-2 in Health Workers and Octogenarians After Vaccination With the BNT162b2 mRNA Vaccine","volume":"96","author":"Terpos","year":"2021","journal-title":"Am J Hematol"},{"key":"B14","article-title":"Safety, Tolerability, and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Healthy Children and Adolescents: A Double-Blind, Randomised, Controlled, Phase 1\/2 Clinical Trial","volume":"21","author":"Han","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B15","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1473-3099(21)00462-X","article-title":"Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, BBIBP-CorV, in People Younger Than 18 Years: A Randomised, Double-Blind, Controlled, Phase 1\/2 Trial","volume":"22","author":"Xia","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107456","article-title":"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents","volume":"385","author":"Frenck","year":"2021","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109522","article-title":"Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents","volume":"385","author":"Ali","year":"2021","journal-title":"New Engl J Med"},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciab845","article-title":"Safety and Immunogenicity of a Recombinant Adenovirus Type-5-Vectored COVID-19 Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged 6 Years and Above: A Randomised, Double-Blind, Placebo-Controlled, Phase 2b Trial","author":"Zhu","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2021-052173","article-title":"Mild SARS-CoV-2 Infections and Neutralizing Antibody Titers","volume":"148","author":"Bonfante","year":"2021","journal-title":"Pediatrics"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.157963","article-title":"Binding and Neutralizing Antibody Responses to SARS-CoV-2 in Very Young Children Exceed Those in Adults","volume":"7","author":"Karron","year":"2022","journal-title":"JCI Insight"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00907-20","article-title":"Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated With COVID-19 Infection","volume":"11","author":"Fidel","year":"2020","journal-title":"mBio"},{"key":"B23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa2116298","article-title":"Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age","volume":"386","author":"Walter","year":"2022","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.595539","article-title":"Cross-Immunization Against Respiratory Coronaviruses May Protect Children From SARS-CoV2: More Than a Simple Hypothesis","volume":"8","author":"Piccaluga","year":"2020","journal-title":"Front Pediatrics"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00085-21","article-title":"Analysis of the Long-Term Impact on Cellular Immunity in COVID-19-Recovered Individuals Reveals a Profound NKT Cell Impairment","volume":"12","author":"Liu","year":"2021","journal-title":"mBio"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2021.2022440","article-title":"Omicron Variant Showed Lower Neutralizing Sensitivity Than Other SARS-CoV-2 Variants to Immune Sera Elicited by Vaccines After Boost","volume":"11","author":"Ai","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taac039","article-title":"Booster Dose of the Inactivated COVID-19 Vaccine BBV152 (Covaxin) Enhances the Neutralizing Antibody Response Against Alpha, Beta, Delta and Omicron Variants of Concern","author":"Deshpande","year":"2022","journal-title":"J Travel Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00094-0","article-title":"Heterologous Versus Homologous COVID-19 Booster Vaccination in Previous Recipients of Two Doses of CoronaVac COVID-19 Vaccine in Brazil (RHH-001): A Phase 4, non-Inferiority, Single Blind, Randomised Study","volume":"399","author":"Costa Clemens","year":"2022","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2022.2030200","article-title":"Homologous or Heterologous Booster of Inactivated Vaccine Reduces SARS-CoV-2 Omicron Variant Escape From Neutralizing Antibodies","volume":"11","author":"Wang","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"B30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41392-022-00920-4","article-title":"Three Doses of Prototypic SARS-CoV-2 Inactivated Vaccine Induce Cross-Protection Against its Variants of Concern","volume":"7","author":"Xie","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2022.2044271","article-title":"Three Doses of an Inactivation-Based COVID-19 Vaccine Induces Cross-Neutralizing Immunity Against the SARS CoV-2 Omicron Variant","volume":"11","author":"Yu","year":"2022","journal-title":"Emerg Microbes Infect"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.898151\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T13:12:01Z","timestamp":1656076321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.898151\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,24]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2022.898151"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.898151","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2022,6,24]]},"article-number":"898151"}}